1. Market Research
  2. > Percutaneous Coronary Intervention – Pipeline Review, H1 2013

Percutaneous Coronary Intervention – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 51 pages

Percutaneous Coronary Intervention – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Percutaneous Coronary Intervention - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Percutaneous Coronary Intervention, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Percutaneous Coronary Intervention. Percutaneous Coronary Intervention - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Percutaneous Coronary Intervention.
- A review of the Percutaneous Coronary Intervention products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Percutaneous Coronary Intervention pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Percutaneous Coronary Intervention.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Percutaneous Coronary Intervention pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Percutaneous Coronary Intervention - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Percutaneous Coronary Intervention Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Percutaneous Coronary Intervention 7
Percutaneous Coronary Intervention Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Percutaneous Coronary Intervention Therapeutics - Products under Development by Companies 14
Companies Involved in Percutaneous Coronary Intervention Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
Eli Lilly and Company 16
Reliance Life Sciences Pvt. Ltd. 17
Momenta Pharmaceuticals, Inc. 18
Regado Biosciences. 19
Lee's Pharmaceutical Holdings Limited 20
Pfenex Inc. 21
Percutaneous Coronary Intervention - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
adomiparin - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
REG-1 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
cangrelor - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
inclacumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
prasugrel hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
ZK-001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
abciximab biosimilar - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Abciximab Biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Percutaneous Coronary Intervention Therapeutics - Drug Profile Updates 40
Percutaneous Coronary Intervention Therapeutics - Dormant Products 45
Percutaneous Coronary Intervention - Product Development Milestones 46
Featured News and Press Releases 46
Oct 23, 2012: Daiichi Sankyo And Eli Lilly Announce Results From New Retrospective Studies In Acute Coronary Syndromes-Percutaneous Coronary Intervention Patients Treated With Effient 46
Jul 02, 2012: The Medicines Company Expects Cangrelor Phase III Trial Enrollment Completion In 2012 47
Nov 16, 2011: New Analysis Of Data Presented At AHA Shows Effects Of Effient On Cardiovascular Events In STEMI Patients 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51



List of Tables

Number of Products Under Development for Percutaneous Coronary Intervention, H1 2013 7
Products under Development for Percutaneous Coronary Intervention - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
F. Hoffmann-La Roche Ltd., H1 2013 15
Eli Lilly and Company, H1 2013 16
Reliance Life Sciences Pvt. Ltd., H1 2013 17
Momenta Pharmaceuticals, Inc., H1 2013 18
Regado Biosciences., H1 2013 19
Lee's Pharmaceutical Holdings Limited, H1 2013 20
Pfenex Inc., H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 26
Percutaneous Coronary Intervention Therapeutics - Drug Profile Updates 40
Percutaneous Coronary Intervention Therapeutics - Dormant Products 45



List of Figures

Number of Products under Development for Percutaneous Coronary Intervention, H1 2013 7
Products under Development for Percutaneous Coronary Intervention - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 22
Assessment by Route of Administration, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Molecule Type, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.